keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer surgery

keyword
https://www.readbyqxmd.com/read/29779035/combined-coronary-artery-bypass-graft-cabg-surgery-and-lung-resection-for-lung-cancer-in-patients-more-than-50-years-of-age
#1
Ban Liu, Chao Chen, Chang Gu, Qianfan Li, Jingjing Liu, Yiwei Pu, Yu Lin, Zilun Wei, Zhi Li, Yangyang Zhang
BACKGROUND The co-existence of coronary heart disease (CHD) and lung cancer is increasing in an increasingly aging population. The aim of this study was to evaluate patient outcome from combined off-pump coronary artery bypass graft (CABG) surgery and lung resection in patients more than 50 years-of-age. MATERIAL AND METHODS A retrospective clinical study of 23 patients with a mean age of 70.2±8.4 years (range, 51-86 years) included 18 men and five women with CHD and lung cancer who underwent a single operation with combined off-pump CABG surgery and lung resection, for non-small cell lung cancer (NSCLC) (n=22) and small cell lung cancer (n=1)...
May 20, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29776444/mediastinal-staging-of-non-small-cell-lung-cancer-by-endobronchial-and-endoscopic-ultrasonography-with-or-without-additional-surgical-mediastinoscopy-mediastrial-study-protocol-of-a-multicenter-randomised-controlled-trial
#2
Jelle E Bousema, Marcel G W Dijkgraaf, Nicole E Papen-Botterhuis, Hermien W Schreurs, Jos G Maessen, Erik H van der Heijden, Willem H Steup, Jerry Braun, Valentin J J M Noyez, Fieke Hoeijmakers, Naomi Beck, Martijn van Dorp, Niels J M Claessens, Birgitta I Hiddinga, Johannes M A Daniels, David J Heineman, Harmen R Zandbergen, Ad F T M Verhagen, Paul E van Schil, Jouke T Annema, Frank J C van den Broek
BACKGROUND: In case of suspicious lymph nodes on computed tomography (CT) or fluorodeoxyglucose positron emission tomography (FDG-PET), advanced tumour size or central tumour location in patients with suspected non-small cell lung cancer (NSCLC), Dutch and European guidelines recommend mediastinal staging by endosonography (endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)) with sampling of mediastinal lymph nodes. If biopsy results from endosonography turn out negative, additional surgical staging of the mediastinum by mediastinoscopy is advised to prevent unnecessary lung resection due to false negative endosonography findings...
May 18, 2018: BMC Surgery
https://www.readbyqxmd.com/read/29775109/outcomes-of-surgery-as-part-of-the-management-of-metastatic-non-small-cell-lung-cancer-a-surveillance-epidemiology-and-end-results-database-analysis
#3
Omar Abdel-Rahman
The role of local treatment in patients with oligometastatic non-small-cell lung cancer (NSCLC) is a subject of ongoing debate. This study assessed the survival impact of combined surgery to the primary tumor and metastatic disease in the management of metastatic NSCLC. Stage IV NSCLC patients at presentation, diagnosed from 2004 to 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TN stage, and site of metastases)...
April 21, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29773328/molecular-and-immune-biomarker-testing-in-squamous-cell-lung-cancer-effect-of-current-and-future-therapies-and-technologies
#4
REVIEW
Fred R Hirsch, Keith M Kerr, Paul A Bunn, Edward S Kim, Coleman Obasaju, Maurice Pérol, Philip Bonomi, Jeffrey D Bradley, David Gandara, James R Jett, Corey J Langer, Ronald B Natale, Silvia Novello, Luis Paz-Ares, Suresh S Ramalingam, Martin Reck, Craig H Reynolds, Egbert F Smit, Mark A Socinski, David R Spigel, Thomas E Stinchcombe, Johan F Vansteenkiste, Heather Wakelee, Nick Thatcher
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC...
March 21, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29771775/photodynamic-therapy-for-bronchial-microscopic-residual-disease-after-resection-in-lung-cancer
#5
Hiren J Mehta, Abhishek Biswas, Sebastian Fernandez-Bussy, Mauricio Pipkin, Tiago Machuca, Michael A Jantz
BACKGROUND: The goal of lung cancer surgery is a complete tumor resection (R0 resection) with clear margins. 4% to 5% of resections have microscopic residual disease associated with worse prognosis. Definitive management is resection of residual tumor, which may not be tolerated by many patients, and definitive management is not well studied in these patients. We treated patients with stage I cancer and bronchial mucosal residual disease (MRD) with bronchoscopic photodynamic therapy (PDT)...
May 16, 2018: Journal of Bronchology & Interventional Pulmonology
https://www.readbyqxmd.com/read/29769148/current-landscape-and-future-of-dual-anti-ctla4-and-pd-1-pd-l1-blockade-immunotherapy-in-cancer-lessons-learned-from-clinical-trials-with-melanoma-and-non-small-cell-lung-cancer-nsclc
#6
REVIEW
Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R Cruz, Sunandana Chandra, Jaehyuk Choi, Francis Giles
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens...
May 16, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29767820/-role-of-visceral-surgery-in-oligometastases-of-non-gastrointestinal-tumors
#7
REVIEW
R Wahba, D Stippel, C Bruns
BACKGROUND: Patients with oligometastatic disease can benefit from local treatment of the metastases. Under these premises the resection of liver metastases and visceral metastases of non-gastrointestinal tumors is performed increasingly more frequently in selected patients. The aim of this study was to evaluate the role of visceral oncological surgery in hepatic oligometastatic disease of non-gastrointestinal tumors according to the currently available literature. MATERIAL AND METHODS: A systematic search of MEDLINE and PubMed was carried out focusing on the topics of oligometastases, liver resection and metastectomy for breast cancer, renal cell carcinoma, malignant melanoma, ovarian cancer and non-small cell lung cancer...
May 16, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29764593/-stereotactic-body-radiotherapy-for-centrally-located-non-small-cell-lung-cancer
#8
Yuming Wan, Jing Huang, Feng Xu
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure...
May 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29764586/-relationship-between-fgfr1-gene-regulation-of-circulating-tumor-cells-and-clinical-features-of-non-small-cell-lung-cancer
#9
Lei Liu, Cheng Huang, Li Li, Naixin Liang, Shanqing Li
BACKGROUND: The methods of detection for recurrence and metastasis in patients with non-small cell lung cancer (NSCLC) have hysteresis and one-sidedness. This study summarizes the relationship between the circulating tumor cell (CTC) in peripheral blood, expression of fibroblast growth factor receptor 1 (FGFR1) and clinic pathological features in 30 patients with NSCLC so as to provide new ideas for the detection of tumor recurrence and metastasis. METHODS: To analyze the clinical data and CTC detection data of 30 cases of NSCLC in Department of Thoracic Surgery, Peking Union Medical College Hospital from November 2016 to June 2017...
May 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29760791/serum-vegf-levels-in-the-early-diagnosis-and-severity-assessment-of-non-small-cell-lung-cancer
#10
Yanzhen Lai, Xueping Wang, Tao Zeng, Shan Xing, Shuqin Dai, Junye Wang, Shulin Chen, Xiaohui Li, Ying Xie, Yuanying Zhu, Wanli Liu
Background: Effective biomarkers are essential to the differential diagnosis and severity assessment of non-small cell lung cancer (NSCLC). This study explored the use of the serum vascular endothelial growth factor (VEGF) levels as a biomarker with the aim of achieving better management of NSCLC. Methods: Serum VEGF levels were assayed via enzyme-linked immunosorbent assay in 180 patients with NSCLC, 136 patients with benign pulmonary nodules, and 119 healthy controls. We additionally detected the serum concentration of three traditional biomarkers-carcinoembryonic antigen (CEA), cancer antigen (CA)-125, and cytokeratin 19 fragments (Cyfra 21-1)-to comparatively evaluate the efficiency and diagnostic value of VEGF in patients with NSCLC...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29760563/durvalumab-a-potential-maintenance-therapy-in-surgery-ineligible-non-small-cell-lung-cancer
#11
REVIEW
Michael R Shafique, Lary A Robinson, Scott Antonia
Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung cancer, particularly with the introduction and dissemination of checkpoint inhibitors, very little progress has been made in the treatment of stage III lung cancer. In this article, we discuss the general staging criteria and treatment options for stage III lung cancer...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29756124/functional-promoter-rs189037-variant-of-atm-is-associated-with-decrease-in-lung-diffusing-capacity-after-irradiation-for-non-small-cell-lung-cancer
#12
Jose Luis Lopez Guerra, Yi-Peng Song, Quynh-Nhu Nguyen, Daniel R Gomez, Zhongxing Liao, Ting Xu
Objective: Single-nucleotide polymorphisms (SNPs) in the ataxia telangiectasia-mutated gene ATM have been linked with pneumonitis after radiotherapy for lung cancer but have not been evaluated in terms of pulmonary function impairment. Here we investigated potential associations between SNPs in ATM and changes in diffusing capacity of the lung for carbon monoxide (DLCO) in patients with non-small-cell lung cancer (NSCLC) after radiotherapy. Methods: From November 1998 through June 2009, 448 consecutive patients with inoperable primary NSCLC underwent definitive (≥60 Gy) radiotherapy, with or without chemotherapy...
March 2018: Chronic Diseases and Translational Medicine
https://www.readbyqxmd.com/read/29755104/-multidisciplinary-approach-to-recurrence-after-resection-of-primary-lung-cancer
#13
Mitsuhiro Kamiyoshihara, Hitoshi Igai, Takashi Ibe, Fumi Ohsawa, Ryohei Yoshikawa, Kimihiro Shimizu, Akira Mogi, Ken Shirabe, Hiroyuki Kuwano
BACKGROUND: The standard approach for treating recurrence after complete resection of primary non-small cell lung cancer has been controversial. We present here a multidisciplinary strategy for postoperative recurrence in patients with primary lung cancer. PATIENTS AND METHODS: Over the last 7 years, we examined the disease-free survival and overall survival of 70 patients who underwent multidisciplinary treatment for recurrence after surgical resection of primary lung cancer...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755102/-multimodality-therapy-for-lung-cancer-with-chest-wall-invasion
#14
Koji Kawaguchi, Kohei Yokoi
The standard therapy for patients with T3N0-1M0 non-small cell lung cancer (NSCLC) involving the chest wall is considered initial resection and adjuvant chemotherapy. However, the compliance of adjuvant therapy is relatively low, and the prognosis for those patients has not been satisfactory. We therefore advocated a new strategy of induction chemoradiotherapy followed by surgery and conducted a prospective, multi-institutional phaseⅡ trial with the aim of improving the survival. The mature results of this trial showed the treatment strategy to be safe and effective with a high rate of pathologic response...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755101/-outcome-of-surgical-treatment-of-locally-advanced-lung-cancer-after-induction-chemoradiotherapy
#15
Masayuki Tanahashi, Haruhiro Yukiue, Eriko Suzuki, Naoko Yoshii, Shinsuke Kitazawa, Yasunori Kaminuma, Hiroshi Niwa
OBJECTIVE: The outcome of surgical treatment of non-small-cell lung cancer after induction chemoradiotherapy was investigated. SUBJECTS: The subjects were 74 patients with non-small-cell lung cancer who received induction chemoradiotherapy( ICRT) between 1998 and 2016. ICRT was administered to pT3 lung cancer invading the chest wall(20 patients), pT4 lung cancer invading the adjacent organ(22 patients), and cN2 lung cancer(32 patients). cN2 was confirmed by mediastinoscopy(13 patients) and endobronchial ultrasound-guided transbronchial needle aspiration(EBUS-TBNA)(19 patients)...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755100/-induction-chemoradiotherapy-for-locally-advanced-non-small-cell-lung-cancer
#16
Akihiro Miura, Junichi Soh, Kazuhiko Shien, Hiromasa Yamamoto, Shinichi Toyooka
The management of locally advanced non-small cell lung cancer (LA-NSCLC) is still controversial, because of complicated patient status and poor prognosis. The purpose of this study was to evaluate the treatment results for induction chemoradiotherapy (iCRT) followed by surgery for LA-NSCLC. From 1999 to 2016, 157 patients were surgically treated after iCRT in our hospital, and their median follow-up was 43 months. Overall survival( OS) was 66.8%, and relapse-free survival( RFS) was 52.0%. The poor prognostic factor in OS by multivariate analysis was lower-lobe origin, incomplete radiotherapy, reoperation, and RFS was lower-lobe origin...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755097/-expectation-for-surgery-in-multi-modality-treatment-in-non-small-cell-lung-cancer
#17
Kenji Sugio
Clinical N2-stageⅢA non-small cell lung cancer(NSCLC) is known to be quite heterogeneous. Many clinical trials proved the effect of postoperative adjuvant chemotherapy for locally advanced NSCLC, which is recommended as grade C1 by Clinical Guideline for Lung Cancer, however, induction treatment for clinical N2-stageⅢA remains still controversial. We showed retrospective data of concurrent chemoradiotherapy using S-1 and cisplatin followed by surgery, which may provide a better prognosis for locally advanced NSCLC patients...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755096/-role-of-surgery-in-multimodality-treatment-for-non-small-cell-lung-cancer-current-status-and-future-perspectives
#18
Toshiyuki Shima, Kyohei Masai, Tomoyuki Hishida, Kaoru Kaseda, Kohei Hashimoto, Yusuke Takahashi, Takashi Otsuka, Hisao Asamura
Recent improvement of outcomes for resected non-small cell lung cancer (NSCLC) has been contributed not only by increased detection of early-stage disease and improvement of preoperative diagnosis/perioperative management but also by improvement of multimodality treatment. The introduction of newly developed systemic therapies including molecular targeted agents and immune checkpoint inhibitors dramatically changed clinical outcomes of advanced NSCLC. Accordingly, the role of surgery during the multimodality treatment will be changed more than ever...
April 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755082/-pulmonary-pleomorphic-carcinoma-relapsed-after-surgery-surviving-long-term-by-chemotherapy-and-nivolumab
#19
Osamu Kawamata, Toshihiro Murata, Masashi Uda
A 60'-year-old man was referred to our hospital because of nodular shadow found at mass screening. We diagnosed the tumor as non-small cell lung cancer by transbronchial biopsy. Chest computed tomography showed a tumor shadow of 3 cm in diameter with cavity. Right middle lobectomy was performed and the pathological diagnosis was pleomorphic carcinoma of the lung. The tumor recurrence was found at 10 months after surgery, and was treated with cisplatin, docetaxel plus bevacizumab for 6 cycles. A complete remission was achieved, but regrowth at 5 months after chemotherapy was noted...
May 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://www.readbyqxmd.com/read/29755071/-salvage-surgery-after-radical-chemotherapy-for-n3-non-small-cell-lung-cancer
#20
Takehiko Shimoyama, Bumpei Kimura
A 49-year-old man was admitted to our hospital for an abnormal chest shadow. Computed tomography showed a pulmonary nodular shadow in the right upper lobe and swelling of the right hilar, mediastinal and supraclavicular lymph nodes. A positron emission tomography(PET) scan showed fluorodeoxyglucose accumulation in the tumor and swollen lymph nodes. He was diagnosed with stage cT1aN3M0 (ⅢB) pulmonary adenocarcinoma and was treated with a combination of cisplatin and paclitaxel. After 6 cycles of chemotherapy, serum carcinoembryonic antigen (CEA) level was markedly decreased...
March 2018: Kyobu Geka. the Japanese Journal of Thoracic Surgery
keyword
keyword
10512
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"